• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[后肾腺瘤:2例报告及文献复习。]

[Adenoma metanephric: Report of 2 cases and bibliographic review.].

作者信息

Rodríguez-Zarco Enrique, Vallejo-Benítez Ana, Farfán-López Francisco Javier, Vilches-Arenas Ángel, Pereira-Gallardo Sofía, Vázquez-Ramírez Francisco Javier

机构信息

Servicio de Anatomía Patológica. Hospital Universitario Virgen Macarena. Sevilla. España.

Servicio de Anatomía Patológica. Hospital Universitario Virgen del Rocío. Sevilla. España.

出版信息

Arch Esp Urol. 2017 Nov;70(9):792-796.

PMID:29099381
Abstract

OBJECTIVE

Two cases of metanephric adenoma are presented, a rare benign renal tumor, and a literature review is done under the current WHO classification (2016).

METHODS

Standard histopathological study was performed with hematoxylin-eosin and immunohistochemistry to analyze the expression of WT, Vimentin, Racemase, CK7, CD10 and RCC.

RESULTS

Neoplasms of 3 and 4.5 cm, histologically, exhibiting tubulopapillary architecture. There was no evidence of significant nuclear atypia and mitotic figures. Immunohistochemical study showed positive immunoreaction for WT1 and Vimentin in tumor cells.

CONCLUSIONS

Two new cases of metanephric adenoma are presented and a review of the literature was performed in order to discuss the prognosis and differential diagnosis of metanephric adenoma. This is a rare tumor and its diagnosis lies on its morphology and its immunohistochemical profile.

摘要

目的

报告两例后肾腺瘤(一种罕见的良性肾肿瘤),并根据世界卫生组织(2016年)的现行分类进行文献综述。

方法

采用苏木精-伊红染色和免疫组织化学进行标准组织病理学研究,以分析WT、波形蛋白、消旋酶、CK7、CD10和肾细胞癌(RCC)的表达。

结果

肿瘤大小分别为3cm和4.5cm,组织学上呈现出管状乳头结构。没有明显核异型性和有丝分裂象的证据。免疫组织化学研究显示肿瘤细胞中WT1和波形蛋白呈阳性免疫反应。

结论

报告了两例新的后肾腺瘤病例,并进行文献综述以讨论后肾腺瘤的预后和鉴别诊断。这是一种罕见肿瘤,其诊断取决于其形态学和免疫组织化学特征。

相似文献

1
[Adenoma metanephric: Report of 2 cases and bibliographic review.].[后肾腺瘤:2例报告及文献复习。]
Arch Esp Urol. 2017 Nov;70(9):792-796.
2
Immunohistochemical phenotype and molecular pathological characteristics of metanephric adenoma.后肾腺瘤的免疫组织化学表型及分子病理学特征
Int J Clin Exp Pathol. 2015 Jun 1;8(6):6031-6. eCollection 2015.
3
[Clinicopathological features and differential diagnosis of metanephric adenoma: a report of sixteen cases].[肾母细胞瘤的临床病理特征及鉴别诊断:附16例报告]
Beijing Da Xue Xue Bao Yi Xue Ban. 2016 Aug 18;48(4):598-602.
4
[Metanephric adenoma of kidney: a clinicopathologic study of eight cases].
Zhonghua Bing Li Xue Za Zhi. 2014 Mar;43(3):154-7.
5
Multifocal metanephric adenoma in childhood.
Pathol Int. 2009 Jan;59(1):49-52. doi: 10.1111/j.1440-1827.2008.02324.x.
6
Fine needle aspiration biopsy of metanephric adenoma: a case report.后肾腺瘤的细针穿刺活检:一例报告
Acta Cytol. 2009 May-Jun;53(3):327-31. doi: 10.1159/000325319.
7
Metanephric Adenoma in the Pediatric Population: Diagnostic Challenges and Follow-up.儿童人群中的后肾腺瘤:诊断挑战与随访
Urology. 2018 Oct;120:211-215. doi: 10.1016/j.urology.2018.06.042. Epub 2018 Jul 10.
8
Metanephric adenoma: molecular study and review of the literature.后肾腺瘤:分子研究和文献复习。
Oncotarget. 2022 Feb 17;13:387-392. doi: 10.18632/oncotarget.28192. eCollection 2022.
9
Congenital renal tumor: metanephric adenoma, nephrogenic rest, or malignancy?先天性肾肿瘤:后肾腺瘤、肾源性残留还是恶性肿瘤?
Pediatr Dev Pathol. 2015 May-Jun;18(3):245-50. doi: 10.2350/15-01-1595-CR.1. Epub 2015 Mar 3.
10
Metanephric adenoma: the utility of immunohistochemical and cytogenetic analyses in differential diagnosis, including solid variant papillary renal cell carcinoma and epithelial-predominant nephroblastoma.后肾腺瘤:免疫组织化学和细胞遗传学分析在鉴别诊断中的应用,包括实性变异型乳头状肾细胞癌和上皮优势型肾母细胞瘤。
Mod Pathol. 2015 Sep;28(9):1236-48. doi: 10.1038/modpathol.2015.81. Epub 2015 Aug 7.

引用本文的文献

1
Metanephric adenoma: molecular study and review of the literature.后肾腺瘤:分子研究和文献复习。
Oncotarget. 2022 Feb 17;13:387-392. doi: 10.18632/oncotarget.28192. eCollection 2022.